Last reviewed · How we verify

NCT03836521

Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry

Recruiting now Last updated 11 February 2019
What this trial tests

trial testing Transcatheter aortic valve replacement in Bicuspid Aortic Valve in 2,000 participants. Currently enrolling.

Timeline
15 August 2016
Primary endpoint
15 August 2028
15 August 2028

Quick facts

Lead sponsorCedars-Sinai Medical Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date15 August 2016
Primary completion15 August 2028
Estimated completion15 August 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cedars-Sinai Medical Center

Who can join

Adults 19 to 129, any sex, with Bicuspid Aortic Valve. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the procedural and clinical outcomes of patients with bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement.
    Yoon SH, Kim WK, Dhoble A, Milhorini Pio S, et al · · 2020 · cited 203× · PMID 32854836 · DOI 10.1016/j.jacc.2020.07.005

Verify or expand the search:

Other trials of Transcatheter aortic valve replacement

Trials testing the same drug.

Other recruiting trials for Bicuspid Aortic Valve

Currently open trials in the same condition.

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03836521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing